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RA has been shown to play a major role in myeloid differentiation both in vitro' and in vivo.34 A specific cytogenetic abnormality, the translocation of a portion of the long arm of chromosome 17 onto the long arm of chromosome 15, is associated with human acute promyelocytic leukemia (A").' -' ' The t( 15; 17) creates a promyelocyte-RA receptor (PML-RAR) fusion gene between the C terminus of the RARa and the amino terminal region of a new locus PML."." It has been suggested that the PML-RAR fusion protein might be incapable of responding to normal levels of RA, and that RARa target genes that normally induce myeloid differentiation are blocked, possibly through a dominant negative mechanism."," Complete remission of APL can be obtained by treating patients with all-trans RA3-6 and it has been strongly suggested that this remission was due to the differentiation of leukemic cells in vivo. 6 Lanotte et all3 have isolated a new cell line, NB4, from a patient with APL. Unlike HL-60 cells, this cell line carries the t(15;17) translocation. HL-60 and NB4 cells are morphologically similar and can undergo in vitro granulocytic differentiation when treated with
To investigate the effect of the t( 15; 17) on transactivation capacities, investigators have cotransfected various cell lines with both a wild type RARa and PML-RAR cDNAs subcloned into an expression vector,"." and a set of chloramphenycolacetyltransferase (CAT) reporter plasmids containing various RA response elements. Different cell lines were used for cotransfection. These experiments indicated that two PML-RAR isoforms had comparable altered transactivation capacities relative to wild-type RARa. However, because of cell-specific and promoter-specific variations, a conclusive test will require identifying PML-RAR target genes crucial for myeloid differentiation. A major limitation of the experiments described above was that they could not provide information on the effects of the PML-RAR translocation on endogenous genes that are involved in the control of cell growth and differentiation of myeloid leukemia cells. Other limitations of these experiments were that they only involved mRNA was observed in both cell lines, but was considerably delayed in NB4 cells that carry the t(l5;17) translocation characteristic of acute promyelocytic leukemia. W e have found that multiple mechanisms were involved in the control of mbn mRNA expression. These mechanisms were different in HL-60 and NB4 cells. Our results show that in HL-6 0 cells, all-trans retinoic acid rapidly decreased transcription of mbn. In contrast, in the t(l5;17)-positive NB4 cells treated with all-trans retinoic acid, upregulation of mbn mRNA expression was followed by a late downregulation, both achieved via posttranscriptional mechanisms. cpm/mL of the full-length mbn cDNA probe'' after labeling by random primer DNA-labeling system (Bethesda Research Laboratory, Gaithersburg, MD). Ethidium bromide-stained 28s and 18s recombinant RNA (rRNA) was used as assessment of RNA quantities on filter after transfer.
Nircliar run-on a.ways. Nuclear run-on assay was conducted as described." Nuclei were isolated from HL-60 and NB4 cells before 0.5% Nonidet P40) followed by centrifugation. The RNA was then purified as described" and resuspended in hybridization buffer at I X 106 cpm/mL. and equal numbers of 10% trichloroacetic acid-precipitable counts were added to each hybridization. For the preparation of cDNA probes to detect run-on labeled transcripts, supercoiled plasmid DNA-containing cDNA sequences were applied to a Nytran filter in a slot blot apparatus (Schleicher and Schuell, Keene, NH), as described." Enough plasmid DNA to provide 4.0 pg ofeach insert cDNA sequence was applied to each slot. Slots were then washed three times with 600 pL of 6X SSC. The filters were baked and then prehybridized. hybridized, and washed as above for Northem blot analysis.' except that after the high-stringency wash they were incubated at 37°C for 30 minutes in IO pglmL RNase A in 2X SSC before drying and exposure to X-AR5 film (Eastman Kodak. Rochester, NY). The 28s rRNA cDNA" was a gift from H. Hanafusa's laboratory (Rockefeller University, New York, NY). 28s rRNA was unchanged during RA-induced diffmntiation of HL60 cells.' Human CD18 and myeloperoxidase (MPO) cDNAs were obtained from ATCC.
RESULTS
Different kinetics of mbn mRNA expression in HL-60 and NB4 cells treated with all-trans RA. In both H M O and NEM cells, mbn was eventually downregulated, but at different times. In HL-60 cells, mbn mRNA was drastically downregulated as early as 2 hours after treatment with all-trans RA (Fig IA) . Early downregulation of mbn mRNA expression was not observed in NEM cells treated under the same conditions with all-trans RA. Instead, upregulation was observed 24 hours after treatment. This upregulation was followed by downregulation starting 4 days afier treatment (Fig I B) . 
of this mRNA (data not shown). In order to correlate the different kinetics of mbn mRNA expression to the rates of differentiation and growth of HL-60 and NB4 cells treated with all-trans RA, cells were stained with Wright/ Giemsa and submitted to cell cycle analy~is.'~ By 3 days of treatment, differentiation was detected in HL-60 cells but not in NB4 cells, whereas by 6 days the percent of neutrophils was almost identical in both cell lines (Table 1) . In both HL-60 and NB4 cells, the percentage of cells in the S phase of the cell cycle was decreased by more than 30% after 3 days of treatment with all-trans RA. This decrease was more pronounced by 4 days in HL-60 (55.9%) than in NB4 cells (44.34%) ( Table 2 ). In both HL-60 and NB4 cells, no precise time point correlation could be established between differentiation, withdrawal from the cell cycle, and the kinetics of mbn mRNA downregulation. However, our results showed that HL-60 cells, where mbn mRNA decreased early after treatment by all-trans RA, were more sensitive than NB4 cells to the differentiation effects of this inducer.
Early transcriptional downregulation of mbn mRNA expression in HL-60 cells. Nuclear run-on transcription assays were performed to examine whether all-trans RA mediated transcriptional regulation of mbn mRNA expression. In HL-60 cells, mbn mRNA expression was transcriptionally downregulated by 66.6% and 98.3% after 2 hours and 24 hours, respectively, of all-trans RA treatment as measured by scanning densitometry (Fig 2A) . This was consistent with the results obtained on the Northern blot as described above (Fig 1A) . In contrast, no significant transcriptional regulation was detected in NB4 cells treated with all-trans RA for 2, 16, and 24 hours (Fig 2B and Table 3 ). Therefore, upregulation of mbn mRNA observed on the Northern blot at 24 hours (Fig 1B) was likely to be the result of increased stabilization of mbn mRNA. No significant transcriptional regulation of mbn expression was observed in NB4 cells treated for 2, 3, and 4 days with all-trans RA, whereas the level of the 28s rRNA remained unchanged (Fig 2C and Table 3 ). As previously observed with HL-60 ~e l l s ,~~,~~ in NB4 cells CD18 mRNA was transcriptionally upregulated early after treatment with all-trans RA, whereas MPO was transcriptionally 477 downregulated after 2 and 3 days (Fig 2C and Table 3 ). Therefore, downregulation of mbn mRNA observed in NB4 cells treated for 4 days with this inducer (Fig 1B) was not correlated with transcriptional mechanisms.
Protein factor($ are involved in mbn mRNA expression. We have tested the effect of the protein synthesis inhibitor cycloheximide (CHX) on the expression of mbn mRNA in both HL-60 and NB4 cells. Treatment of HL-60 cells with CHX resulted in superinduction of mbn mRNA expression with a peak at 4 hours after treatment (Fig 3A) . This result suggests that, in HL-60 cells, a protein factor(s) maintaining a low basal mbn mRNA level was inhibited by CHX. After this superinduction, mbn mRNA level decreased progressively and no mRNA was detected after 16 hours ( Fig  3A) . Similar results were observed when HL-60 cells were treated with both all-trans RA and CHX. These results suggest that transcriptional downregulation of mbn expression was factor dependent, although downregulation of mbn mRNA expression was still observed at 2 hours after treatment ( Fig  3B) . In contrast, treatment of NB4 cells with CHX did not result in superinduction of mbn mRNA expression. Instead, a progressive decrease was observed when CHX was used either alone (Fig 3C) or in association with all-trans RA ( Fig  3D) . These decreases in mbn mRNA levels were not the results of CHX toxicity on NB4 cells, because their viability after 8 and 24 hours of treatment by CHX was 96.5% and 94.5%, respectively, as assessed by the trypan blue exclusion test. Therefore, these results suggest that the increased mbn mRNA levels observed in NB4 cells treated with all-trans RA were dependent on protein synthesis. Inhibition of a protein factor(s) by CHX resulted in decreased levels of mbn mRNA.
Superinduction of mbn mRNA expression by actinomycin D. Because the effect of protein synthesis inhibitors such as CHX can occur at both transcriptional and posttranscriptional levels, cells were treated with actinomycin D (ActD), an inhibitor of transcription, in the presence or absence of CHX. Superinduction of mbn mRNA expression was observed in both NB4 and HL-60 cells treated for 45 and 90 minutes with ActD alone (Fig 4A and B, respectively) . In NB4 cells, this superinduction was associated with an increased level of mbn mRNA between 45 and 90 minutes ( Fig  4A) . mbn mRNA was also increased when NB4 cells were treated simultaneously with either CHX and ActD (Fig 4A) or with all-trans RA and ActD (Fig 4C) . As a control of transcriptional inhibition by ActD and as reported,25 in HL-60 cells c-fos mRNA was downregulated by ActD and superinduced by CHX (data not shown). Although superinduction of mbn mRNA by ActD was surprising, one interpretation Table 3. of our results could be that in NB4 cells, ActD inhibited a negative transcriptional control on theexpression ofa factor(s) that stabilizes mhn mRNA. The same hypothesis applies to the effect of all-rruns RA, because it increased the level of mhn mRNA in NB4 cells through a posttranscriptional mechanism (Fig IB) . The hypothesis that a factor(s) that stabilizes mhn mRNA is present in NB4 cells is in agreement with the fact that treatment of NB4 cells by CHX results in a progressive decrease of mhn mRNA levels (Fig 3D) . In contrast to NB4. in HL-60 cells the fact that both CHX and ActD resulted in superinduction of mhn mRNA (Figs 3A and 4B) suggests that treatment by these agents provoked downregulation of a negative transcription factor@). This hypothesis was reinforced by the fact that transcriptional down- Our results indicate that multiple mechanisms regulate mhn mRNA expression in the two leukemia cell lines after treatment by all-rruns RA. We have found that although in HL-60 cells mhn mRNA expression was controlled transcriptionally, it was mainly the result of posttranscriptional control in NB4 cells. In both H L 6 0 and NB4 cells, these mechanisms involve protein factors that might be regulated Values are densitometry units as measured by scanning densitometry. NB4 cells before and after exposure to all-trans RA for 2 h (Fig 28) . t See Fig 2C. For personal use only. on November 11, 2017. by guest www.bloodjournal.org From Therefore, the apparent paradox that t( 15; 17) (resulting in the expression of an altered RAR)6 seems to confer alltrans RA sensitivity to APL cells could be explained by the possibility that posttranscriptional mechanisms may regulate genes that are critical to growth and differentiation of these cells.
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Further experiments to test for this possibility will require the identification of mhn transcriptional elements as well as factors and sequences that are involved in the stability of the mhn mRNA. Future experiments will also determine whether the mhn gene regulatory domains contain a sequence under the control of the PML part oft( 15; 17).
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